PMV Pharma Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
54
- Stock Symbol
-
PMVP
- Share Price
-
$1.31
- (As of Thursday Closing)
PMV Pharma General Information
Description
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
Contact Information
Website
www.pmvpharma.comCorporate Office
- 400 Alexander Park Drive
- Suite 301
- Princeton, NJ 08540
- United States
Corporate Office
- 400 Alexander Park Drive
- Suite 301
- Princeton, NJ 08540
- United States
PMV Pharma Stock Performance
As of 19-Nov-2026, PMV Pharma’s stock price is $1.31. Its current market cap is $99M with 75.5M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.31 | $1.22 | $1.02 - $1.91 | $99M | 75.5M | 715K | -$1.56 |
PMV Pharma Financials Summary
As of 30-Sep-2026, PMV Pharma has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 46,893 | (61,805) | (91,436) | (30,630) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (92,227) | (86,118) | (84,320) | (78,872) |
| Net Income | (88,533) | (77,742) | (58,709) | (68,960) |
| Total Assets | 111,404 | 116,562 | 191,288 | 252,152 |
| Total Debt | 138 | 838 | 1,190 | 13,286 |
PMV Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PMV Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
PMV Pharma Comparisons
Industry
Financing
Details
PMV Pharma Competitors (57)
One of PMV Pharma’s 57 competitors is Outlook Therapeutics, a Formerly VC-backed company based in Iselin, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Outlook Therapeutics | Formerly VC-backed | Iselin, NJ | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Valerio Therapeutics | Formerly VC-backed | Paris, France | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Xenetic Biosciences | Corporation | Framingham, MA |
PMV Pharma Patents
PMV Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026228825-A1 | Crystalline forms of plk4 modulating compounds | Pending | 30-Apr-2025 | ||
| AU-2024369826-A1 | Plk4 modulators | Pending | 30-Oct-2023 | ||
| EP-4801907-A1 | Plk4 modulators | Pending | 30-Oct-2023 | ||
| WO-2025096463-A1 | Plk4 modulators | Inactive | 30-Oct-2023 | ||
| AU-2024359526-A1 | Methods of treating conditions with mutant p53 reactivating compounds | Pending | 10-Oct-2023 | A61P35/00 |
PMV Pharma Signals
PMV Pharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.27 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
PMV Pharma FAQs
-
When was PMV Pharma founded?
PMV Pharma was founded in 2013.
-
Where is PMV Pharma headquartered?
PMV Pharma is headquartered in Princeton, NJ.
-
What is the size of PMV Pharma?
PMV Pharma has 54 total employees.
-
What industry is PMV Pharma in?
PMV Pharma’s primary industry is Drug Discovery.
-
Is PMV Pharma a private or public company?
PMV Pharma is a Public company.
-
What is PMV Pharma’s stock symbol?
The ticker symbol for PMV Pharma is PMVP.
-
What is the current stock price of PMV Pharma?
As of 19-Nov-2026 the stock price of PMV Pharma is $1.31.
-
What is the current market cap of PMV Pharma?
The current market capitalization of PMV Pharma is $99M.
-
Who are PMV Pharma’s competitors?
Outlook Therapeutics, Marengo Therapeutics, Valerio Therapeutics, CytomX Therapeutics, and Xenetic Biosciences are some of the 57 competitors of PMV Pharma.
-
What is PMV Pharma’s annual earnings per share (EPS)?
PMV Pharma’s EPS for 12 months was -$1.56.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process